Table 2.
Clinical features of TET-GS patients with or without AD (n 29). .
| Characteristic | TET (N = 12) | TET-AD (N = 17) |
|---|---|---|
| Age (years) | ||
| Mean (median) | 53.75 | 60.82 |
| Range | 45–65 | 38–75 |
| Sex, n (%) | ||
| Male | 8 (67) | 5 (29) |
| Female | 4 (33) | 12 (71) |
| Thymectomy, n (%) | ||
| Yes | 4 (33) | 16 (94) |
| No | 8 (67) | 1 (6) |
| Histological type, n (%) | ||
| Thymoma | 10 (83) | 17 (100) |
| A | 0 | 6 (35%) |
| A B | 0 | 4 (24%) |
| B1 | 0 | 1 (6) |
| B2 | 2 (17) | 2 (12) |
| B1–B2 | 0 | 0 |
| B2–B3 | 1 (8) | 1 (6) |
| B3 | 7 (58) | 3 (18) |
| Not otherwise specified | 0 | 0 |
| Thymic carcinoma | 2 (17) | 0 |
| Stage of disease according to TNM staging, n (%) | ||
| I | 0 | 3 (18) |
| II | 0 | 2 (12) |
| IIIA | 2 (17) | 0 |
| IIIB | 0 | 0 |
| IVA | 5 (42) | 4 (24) |
| IVB | 5 (42) | 8 (47) |
| Myasthenia gravis ,, n (%) | ||
| Yes | 0 | 9 (53) |
| No | 12 (100) | 8 (47) |
| Other autoimmune disorders, n (%) | ||
| PRCA | 0 | 5 (29) |
| Cholitis | 0 | 6 (35) |
| Arthritis | 0 | 3 (18) |
| Thyroiditis | 0 | 4 (24) |
| Other | 0 | 2 (12) |
| Polyautoimmunity | 0 | 7 (41) |
| Second primary cancer, n (%) | ||
| Kaposi’s sarcoma | 0 | 6 (35) |
| Prostate | 0 | 1 (6) |
| Bronchial | 1 (8) | 0 |
| Other | 0 | 1 (6) |
| All type of infection, n (%) | 12 (100) | 16 (94) |
| Typical site: sinopulmonary, n (%) | 10 (83) | 14 (82) |
| Pathogen, n (%) | ||
| Bacteria: Streptococcus pneumoniae | 5 (42) | 6 (35) |
| Virus: cytomegalovirus | 4 (33) | 11 (65) |
| Fungus: Candida | 6 (50) | 9 (53) |
The table reports the groups of TET patients with GS (12 without AD and 17 with AD) along with their clinical characteristics. TMN, tumour, node, metastasis.